GM Advisory Group LLC Invests $350,000 in Standard BioTools Inc. (NASDAQ:LAB)

GM Advisory Group LLC bought a new position in shares of Standard BioTools Inc. (NASDAQ:LAB) during the fourth quarter, Holdings Channel reports. The fund bought 200,000 shares of the company’s stock, valued at approximately $350,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of LAB. Cibc World Markets Corp purchased a new position in Standard BioTools during the 4th quarter worth approximately $48,000. Royce & Associates LP grew its holdings in shares of Standard BioTools by 136.8% during the fourth quarter. Royce & Associates LP now owns 1,455,503 shares of the company’s stock valued at $2,547,000 after buying an additional 840,951 shares in the last quarter. HighTower Advisors LLC raised its position in Standard BioTools by 13.0% during the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock valued at $162,000 after buying an additional 10,690 shares during the period. Bradley & Co. Private Wealth Management LLC purchased a new stake in Standard BioTools in the 4th quarter worth about $314,000. Finally, SG Americas Securities LLC boosted its position in Standard BioTools by 34.2% during the 4th quarter. SG Americas Securities LLC now owns 135,927 shares of the company’s stock worth $238,000 after acquiring an additional 34,670 shares during the period. Institutional investors and hedge funds own 53.74% of the company’s stock.

Standard BioTools Trading Up 1.7 %

NASDAQ LAB opened at $1.18 on Thursday. The company has a market capitalization of $447.20 million, a PE ratio of -1.66 and a beta of 1.62. Standard BioTools Inc. has a 1-year low of $0.99 and a 1-year high of $3.04. The firm’s fifty day simple moving average is $1.42 and its 200-day simple moving average is $1.72.

Insiders Place Their Bets

In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was bought at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the transaction, the director now directly owns 58,846,780 shares of the company’s stock, valued at approximately $62,377,586.80. The trade was a 8.92 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 53.10% of the company’s stock.

Analysts Set New Price Targets

Separately, KeyCorp lowered shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.